Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

作者：Joaquı́n Mateo, Johann S. de Bono, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Mustafa Özgüroğlu, Niven Mehra, Nobuaki Matsubara, Jae Young Joung, Charles Padua, Ernesto Korbenfeld, Jinyu Kang, Helen Marshall, Zhongwu Lai, Alan Barnicle, Christian Poehlein, Natalia Lukashchuk, Maha Hussain · 发表于：Journal of Clinical Oncology · 年份：2023 · DOI：10.1200/jco.23.00339 · 被引用次数：100 · 研究领域：PARP inhibition in cancer therapy、Prostate Cancer Treatment and Research、Cell death mechanisms and regulation

Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.